Type 2 Diabetes
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)
ITRN | {{ defaultRegistry.registryAnchorText }} NCT03214380 {{ currentLocaleObject.registryAnchorText }}
Study Purpose
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
Completed Study
The results of this study are not yet available.
Time Commitment
Your participation in the main study could last up to 39 weeks. At the end of this period, you may be asked to return for additional follow-up blood tests for up to 26 weeks.
Who Participated?
Here you can find out a bit more about the requirements for volunteers who took part in this study
Gender
Age
- Participant must have been diagnosed with type 2 diabetes at least 1 year ago
Participant must have been treated with one of the following for at least 90 days prior to starting the study:
Basal insulin (insulin glargine U-100 [Basaglar/Abasaglar or LANTUS] or U-300, insulin detemir, insulin degludec U-100 or U-200, or neutral protamine Hagedorn [NPH] insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro U-100 or U-200, insulin aspart, insulin glulisine, or regular insulin) OR Premixed analog or human insulin regimens with any basal and bolus insulin combination injected at least twice dailyParticipant must not have been diagnosed with type 1 diabetes or latent autoimmune diabetes in adults
- Participant must not have had emergency treatment for very low blood glucose or poor blood gluecose control in the last 6 months
- Participant must not have used thiazolidinediones, Glucagon-Like Peptide 1 (GLP-1) receptor agonist, or pramlintide within the last 90 days